Insulin Pumps

According to the International Diabetes Federation (IDF), approximately 537 million adults, or 10.5% of the adult population, have diabetes worldwide. This number is expected to rise to approximately 643 million by 2030 and 783 million by 2045. Approximately 90% of this population has type 2 diabetes, and approximately 240 million people are undiagnosed.

Diabetes mellitus is a group of chronic endocrine disorders characterized by high blood glucose or hyperglycemia due to impaired insulin production or utilization. Glucose is the body’s primary source of energy. Insulin is an important hormone manufactured by the pancreas that helps regulate blood glucose levels to keep them in a healthy range.

An electronic automated insulin pump is designed for people with diabetes and replaces burdensome manual multiple daily (insulin) injections (commonly termed “MDI”), or the frequent use of standard needles/syringes or pens. The pump system typically includes a small, discreet cellphone-size handheld device and other components that is worn externally (e.g., clipped to a belt, held in a pocket, or hidden under clothing) that automatically delivers continuous, precise doses of rapid-acting insulin according to the body’s needs.

The multi-billion insulin pumps market, despite recent setbacks, is experiencing a resurgence and is one of the highest-growth medical device markets. In 2023, the combined market for insulin pumps totaled approximately $4.6bn. During the forecast period covered by this report, sales are expected to grow at a healthy, double-digit compound annual growth rate (CAGR) of 17.0%, nearly doubling to an estimated $10bn by 2028.

Market drivers include: a large and underpenetrated diabetes market; ongoing technical improvements and launches of next-generation artificial intelligence/machine-learning (AI/ML)-driven automated pump systems (e.g., MiniMed 780G); availability of simpler patch-pod pumps (e.g., Omnipod and emerging systems); expanding indications to type 2 diabetes, broadening the potential patient pool; and lucrative repeat sales from infusion sets/disposables and related products, among other factors. Limiters include: inflation/macroeconomic factors, high cost; reluctance of some consumers to use automated pumps (versus traditional MDI), intense competition, pricing pressures, and high barriers to entry.

This analysis includes a discussion of products, current revenues and forecast markets, competitors, and opportunities in the global market for insulin pump systems; revenues include sales of automated tubed insulin pumps and tubeless pod-pumps, and various components, including: insulin reservoirs, handheld controllers, and related products/pump supplies, such as disposable infusion sets, inserters, continuous glucose monitoring (CGM) sensors (if sold as part of the pump system versus sold separately*), software/mobile apps, and accessories. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2023–28.

*Note: for more information on the burgeoning $10bn stand-alone CGMs market; see Meddevicetracker’s report, Continuous Glucose Monitoring (CGM) Systems Market.

If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].

Related Medtech Insight articles:

• Medtronic Is Not Going With The EOFlow – Deal Cancelled
• JPM Day 1: Abbott Riding In Tandem With Libre 2 Plus & t:slim X2 News
• ‘Closest To What The Pancreas Would Actually Do’: Medtronic Diabetes Execs On Marketing Plans For MiniMed 780G
• Medtronic MiniMed 780G Data Shows Simplified Meal Management Helps Users With Glycemic Target

Subscribe to Medtech Insight to view these articles and more!